Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.

被引：3
|
作者：
Peng, Zhi
Zhang, Xiaotian
Liang, Han
Zheng, Zhichao
Wang, Zhenning
Liu, Hao
Hu, Jiankun
Sun, Yihong
Zhang, Yanqiao
Yan, Han
Tong, Lin
Xu, Jiahui
Xie, Jessica
Ji, Jiafu
Shen, Lin
机构：
[1] Peking Univ, Canc Hosp & Inst, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res,Dept Gastro, Beijing, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[3] Liaoning Canc Hosp, Shenyang, Peoples R China
[4] China Med Univ, Hosp 1, Dept Surg Oncol, Shenyang, Peoples R China
[5] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[6] Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Precis Med Gastrointestina, Guangzhou, Guangdong, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[8] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[10] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
[11] Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China
[12] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-424-6846-174; 261-492-2769; 283-2511; 261-566-148-2649; 281-318-430; 283-424-6846-5514; 261-566-9690; 6; 4; 3; 2; 291; 1791; 1854; 1704; 239; 92; 5; 38092-22447;
D O I：
10.1200/JCO.2024.42.3_suppl.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：312 / 312
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study
    Li, Ning
    Li, Zhi
    Fu, Qiang
    Zhang, Bin
    Zhang, Jian
    Wan, Xiang-Bin
    Lu, Chao-Min
    Wang, Jin-Bang
    Deng, Wen-Ying
    Ma, Yi-Jie
    Bie, Liang-Yu
    Wang, Meng-Yu
    Li, Jing
    Xia, Qing-Xin
    Wei, Chen
    Luo, Su-Xia
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (04) : 2071 - 2084
  • [12] Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
    Zhang, Qingyuan
    Ouyang, Quchang
    Li, Wei
    Chiu, Joanne
    Yan, Min
    Lu, Yen-Shen
    Sun, Sanyuan
    Li, Huiping
    Du, Yingying
    Wang, Xujuan
    Sun, Tao
    Yin, Yongmei
    Wang, Haibo
    Ye, Feng
    Shen, Kunwei
    Wang, Jingfen
    Pan, Yueyin
    Wang, Shusen
    Yang, Jin
    Wu, Xiaohong
    Dai, Ming-Shen
    Cheng, Jing
    Teng, Yuee
    Su, Fang
    Wu, Xinhong
    He, Jingdong
    Fu, Peifen
    Yang, Lulu
    Xin, Yuan
    Wang, Xiaojia
    Jiang, Zefei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [13] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
    Yamaguchi, K.
    Bang, Y-J.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M-H.
    Sakai, D.
    Chung, H. C.
    Kawakami, H.
    Yabusaki, H.
    Lee, J.
    Saito, K.
    Kawaguchi, Y.
    Kamio, T.
    Kojima, A.
    Sugihara, M.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S899 - S900
  • [14] A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer
    Peng, Jianjun
    Li, Yong
    Xiao, Jianjun
    Liu, Huaqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [15] Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study.
    Chen, Zhanhong
    Wang, Xiaojia
    Huang, Jian
    Zheng, Yabing
    Shao, Xiying
    Cao, Wenming
    Chen, Junqing
    Ye, Weiwu
    Ping, Huang
    Li, Guangliang
    Lei, Lei
    Shi, Lei
    Huang, Yuan
    Zou, Weibin
    Wang, Rong
    Shen, Xia-Bo
    Lou, Caijin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [16] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
    Li, Hongli
    Deng, Jingyu
    Ge, Shaohua
    Zang, Fenglin
    Zhang, Le
    Ren, Peng
    Wang, Baogui
    Cao, Fuliang
    Deng, Ting
    Liu, Rui
    Ning, Tao
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liu, Yong
    Zhou, Dejun
    Liang, Han
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [17] Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study.
    Vieito Villar, Maria
    Simonelli, Matteo
    Eskens, Ferry A. L. M.
    Gil-Martin, Marta
    Yen, Chia-Jui
    Obermannova, Radka
    Chao, Yee
    Zagonel, Vittorina
    Melichar, Bohuslav
    Moreno, Victor
    Yu, Ming-Lung
    Bongiovanni, Alberto
    Calvo, Emiliano
    Rottey, Sylvie
    Machiels, Jean-Pascal
    Gonzalez-Martin, Antonio
    Paz-Ares, Luis
    Chang, Chih-Long
    Mason, Warren
    Lin, Chia-Chi
    Reardon, David
    Garralda, Elena
    Santoro, Armando
    Meng, Robin
    Abbadessa, Giovanni
    Menas, Fatima
    Lee, Helen
    Liu, Qianying
    Combeau, Cecile
    Ternes, Nils
    Massard, Christophe
    CANCER RESEARCH, 2021, 81 (13)
  • [18] A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC)
    Kang, Yoon-Koo
    Shah, Manish A.
    Ohtsu, Atsushi
    Van Cutsem, Eric
    Ajani, Jaffer A.
    van der Horst, Tina
    Harle-Yge, Marie-Laurence
    Piao, Yongzhe
    Althaus, Betsy
    Thuss-Patience, Peter C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [19] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
    Simonelli, M.
    Garralda, E.
    Eskens, F.
    Gil-Martin, M.
    Yen, C-J
    Obermannova, R.
    Chao, Y.
    Lonardi, S.
    Melichar, B.
    Moreno, V
    Yu, M-L
    Bongiovanni, A.
    Calvo, E.
    Rottey, S.
    Machiels, J-P
    Gonzalez-Martin, A.
    Paz-Ares, L.
    Chang, C-L
    Mason, W.
    Lin, C-C
    Reardon, D. A.
    Vieito, M.
    Santoro, A.
    Meng, R.
    Abbadessa, G.
    Menas, F.
    Lee, H.
    Liu, Q.
    Combeau, C.
    Ternes, N.
    Ziti-Ljajic, S.
    Massard, C.
    ESMO OPEN, 2022, 7 (05)
  • [20] Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial
    Andre, F.
    Nadal, J. C.
    Denys, H.
    Goel, S.
    Litchfield, L. M.
    Appiah, A.
    Chen, Y.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1386 - S1387
12345